Daas, Raid M D

The company's founder and CEO,Andrew Hopkins, has said he believes that ‘all new therapies will be designed with the help of AI in the future.’ Hopkins announced yesterday (May 15) that Sumitomo Pharma Co., Ltd. plans to initiate a phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease. It is the third molecule created using Exscientia’s AI-driven drug discovery platform under a collaboration with Sumitomo, referred to as design as a service or DaaS. Hopkins said: “Using AI, we are creating a much more efficient process to design and develop differentiated drug candidates. We believe that all new therapies will be designed with the help of AI in the future.” “With three AI-generated development compounds designed for Sumitomo Pharma, plus our own emerging pipeline, we have repeatedly validated our approach and are on track to achieve our vision of encoding and automating pharmaceutical R&D. Following the successful conclusion of the DaaS partnership for DSP-2342, Sumitomo holds all further development, commercial and economic rights to the compound. However, Exscientia maintains ownership of or economic rights to all compounds in its portfolio outside of the original Sumitomo Pharma agreement. These include EXS21546, an A2A receptor antagonist, GTAEXS617, a CDK7 inhibitor and EXS4318, a selective PKC-theta inhibitor being evaluated in inflammatory diseases by Bristol Myers Squibb. googletag.cmd.push(function () { googletag.display('text-ad1'); }); In addition, two further wholly owned precision oncology development candidates, EXS74539, an LSD1 inhibitor and EXS73565, a MALT1 protease inhibitor, have been announced recently and are currently progressing through IND/CTA-enabling studies. Exscientia is an AI-driven precision medicine company committed to discovering, designing and says its aim is developing the best possible drugs in the fastest and most effective manner. The company developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia says its internal pipeline is focused on leveraging its precision medicine platform in oncology, while their partnered pipeline broadens their approach to other therapeutic areas.

OXFORD, England--( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease. It is the third molecule created utilising Exscientia’s AI-driven drug discovery platform under a collaboration with Sumitomo Pharma, referred to as design as a service or DaaS. “With three AI-generated development compounds designed for Sumitomo Pharma, plus our own emerging pipeline, we have repeatedly validated our approach and are on track to achieve our vision of encoding and automating pharmaceutical R&D,” said Andrew Hopkins, founder and Chief Executive Officer at Exscientia. “Using AI, we are creating a much more efficient process to design and develop differentiated drug candidates. We believe that all new therapies will be designed with the help of AI in the future.” Following the successful conclusion of the DaaS partnership for DSP-2342, Sumitomo Pharma holds all further development, commercial and economic rights to the compound. However, Exscientia maintains ownership of or economic rights to all compounds in its portfolio outside of the original Sumitomo Pharma agreement. These include EXS21546, an A 2A receptor antagonist, GTAEXS617, a CDK7 inhibitor and EXS4318, a selective PKC-theta inhibitor being evaluated in inflammatory diseases by Bristol Myers Squibb. In addition, two further wholly owned precision oncology development candidates, EXS74539, an LSD1 inhibitor and EXS73565, a MALT1 protease inhibitor, have been announced recently and are currently progressing through IND/CTA-enabling studies. About Exscientia Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. Visit us at www.exscientia.ai or follow us on Twitter @exscientiaAI . Forward-Looking Statements This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the performance of Exscientia’s in generative AI platform and the discovery and development of candidate molecules, and the timing and progress of, and data reported from, preclinical studies and clinical trials of Sumitomo Pharma’s and Exscientia’s wholly or partially owned product candidates. Any statement describing Exscientia’s goals, plans, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that macroeconomic conditions and geopolitical events could have on the Company’s business; the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technological developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/ ), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

Pune, India, May 17, 2021 (GLOBE NEWSWIRE) -- The global data as a service market has been estimated to attain a value of USD 5.4 billion in 2021 and is projected to grow at a CAGR of 14% during the forecast period from 2021 to 2030. Data as a service (DaaS) is a cloud service to ensure the availability of critical data in a cost-effective and convenient manner to businesses. The DaaS model works on the principle of risks associated with data management and offloading the load to a third-party cloud-based provider. Regardless of any organization’s structural and geographical barriers, DaaS enables users to access specified useful data on demand. Get Sample Copy of This Report @ Through a single update point, DaaS enables multiple users to use and modify the data. At a particular location, DaaS eliminates redundancy and streamlines operational costs by integrating critical data of businesses. The DaaS technology is used in business for applications including customer intelligence, enterprise resource planning (ERP), customer resource management (CRM), and e-commerce and supply chain management systems. To upkeep SOA (service-oriented architecture) and web services, data as a service is emerging as a fundamental technology. The increasing penetration of high-speed Internet network infrastructure is enabling user to have better access to data with the internet. This is making DaaS a lucrative choice for enterprises. Enterprise data to a significant extent has contributed to the development of DaaS. Additionally, the advent of SOA has reduced the relevance of the specific platform. DaaS can be integrated with and also is similar to software as a service (SaaS) and storage as a service (SaaS) models. The DaaS market is expected to witness substantial growth, as it is providing reduced operational cost and improved workflow process. DaaS is expected to play a vital role in the development of enterprises across various industries, with the growth in the use of big data (complicated data sets) in the professional world. The primary factors expected to pave the way for the growth of the DaaS market globally are cloud-based infrastructure and services, enterprise data syndication, and consumer services trends focused on XaaS (Everything as a Service). Global Data as a Service Market, By Deployment By deployment mode, the global data as a service market has been segmented into public cloud, private cloud, and hybrid cloud. A hybrid cloud platform gives organizations many advantages, such as greater flexibility, compliance, more deployment options, security, and more value from their existing infrastructure. Hybrid cloud computing enables businesses to seamlessly scale up their on-premises infrastructure to the public cloud, when computing and processing demand fluctuates. While keeping highly sensitive data in their own datacenter to meet client needs or regulatory requirements, organizations gain the flexibility and innovation the public cloud provides by running certain workloads in the cloud. Hybrid clouds allow apps and data to move between the two environments. It combines on-premises infrastructure or a private cloud with a public cloud. Many organizations choose a hybrid cloud approach due to business requirements. Global Data as a Service Market, By Organization Size By organization size, the global data as a service market has been segmented into small and medium enterprises and large enterprises. There has been outsourcing of desktop personal computers to lower expenses and improve productivity by SMEs. Thus, the SME segment will dominate the market over the forecast period. Global Data as a Service Market, By End-Users Enquiry Before Buying This Report @ By end-users, the global data as a service market has been segmented into BFSI, healthcare, retail, and information technology and telecom. For the use of software in every strata of life and the proliferation of IT companies, the IT and telecommunication segment will spearhead the market over the forecast period. Global Data as a Service Market, By Region By region, the global data as a service market is segmented as North America, Europe, Asia Pacific, Middle East & Africa, and South America. Over the forecast period, North America will dominate the market. There has been increased adoption of the work from home trend, with the launch of this program by HR. DaaS has the ability to offer customers flexibility in their operation. Among different industry verticals, there have been technological advances, increased use of DaaS devices, and a shift to cloud-based workspace virtualization from traditional desktops, which are adding to the global DaaS market growth in the region. The US, Canada, and Mexico have the major market shares. Some Noted Developments Considered in the Report: COVID-19 Impact on Global Data as a Service Market The QMI team has closely monitored the impact of COVID-19 on the global data as a service market, and it is observed that the demand for data as a service has increased during the pandemic time. It is anticipated to grow at a healthy pace from mid-2021. To control the pandemic, many countries across the globe have enforced strict lockdown norms, which have hampered all kinds of business activities. Due to the COVID-19 pandemic, the healthcare systems have been expanded, and data as a service is being used to offer an operational foundation in the distribution of crucial services. The demand to manage transparency and remove redundancy and forgery of medical research-related data are the basic reasons for the widespread adoption of data as a service in the market. Some Major Findings of Global Data as a Service Market Include: Browse key industry insights spread across 155 pages with 85 market data tables and 41 figures & charts from the report, “Data as a Service Market, By Deployment (Public cloud, private cloud, hybrid cloud). By Organization Size (Small and medium enterprise and large enterprise), By End-users (BFSI, Healthcare, Retail, It and Telecom), By Region (North America, Western Europe, Asia Pacific, Eastern Europe, Middle East, and Rest of the World.) - Market Size & Forecasting 2021-2029” in-depth analysis along with the table of contents (ToC). Buy Now Full Report:  For Query: sales@quincemarketinsights.com or Browse Related Reports: